Marc Tiltman

Group Managing Director at ONLY THE BRAVE HEALTH
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Zug, Zug, Switzerland, CH
Languages
  • French Native or bilingual proficiency
  • English Native or bilingual proficiency

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United Kingdom
    • Business Consulting and Services
    • 1 - 100 Employee
    • Group Managing Director
      • Jun 2022 - Present

    • United Kingdom
    • Business Consulting and Services
    • 1 - 100 Employee
    • Associate
      • Sep 2021 - Oct 2022

    • United Kingdom
    • Business Consulting and Services
    • 1 - 100 Employee
    • Senior Commercial Strategy Consultant
      • Nov 2019 - Sep 2022

    • United Kingdom
    • IT Services and IT Consulting
    • 700 & Above Employee
    • Independent Commercial Strategy Consultant
      • Nov 2019 - Sep 2022

      I support Pharmaceutical and Biotech companies to develop brand strategy and launch plans, building momentum by developing clear strategic assumptions and plans, and handing over to in house teams so that they can drive success.I undertake projects to lead the brand planning process, conduct deep dives into key issues such as competitiveness, patient finding, omnichannel plans or to support launch preparation. I support the team to generate practical, tangible strategies and plans and can also carry that through to support hands on implementation.Recent projects include development of Brand Plans (global and country), launch readiness, multi channel engagement and digital marketing plans, preparation for the entry of competitors, commercial considerations for product acquisitions, application of new technology (eg Artificial Intelligence) in Pharma/Biotech marketing.Therapy areas include Rare Disease, Oncology, Vaccines, Respiratory and Diabetes.

    • Japan
    • Biotechnology Research
    • 700 & Above Employee
    • Global Commercial / Product Strategy Lead, Gattex/Revestive
      • Nov 2016 - Sep 2019

      Senior Director, Global Commercial Product Strategy leading global commercial activities for the rare Gastroenterology (GI) product, Gattex/Revestive for Short Bowel Syndrome.Accelerated product uptake in US and Europe, supported European/Rest of World countries in preparing for launch and implementation of market access strategy and led the launch of paediatric indication globally. Particular areas of focus included US commercial activities and medico-marketing strategy implementation.

    • Global Product Strategy Lead
      • Oct 2017 - Jun 2018

      Ad interim Global Product Strategy, leading the Global cross functional team and co chair of Global Product Strategy Team.Led team through key development milestone reviews for early stage asset and device.

    • Pharmaceutical Manufacturing
    • 200 - 300 Employee
    • European Franchise Head, HPV Vaccines
      • Jul 2013 - Oct 2016

      Leadership of the SPMSD GARDASIL / GARDASIL 9 cross functional franchise team, responsible for:- Marketing strategy to drive the growth of GARDASIL- European launch of GARDASIL 9, leading the cross functional team from initial data to in market launch- Policy initiatives to support the role of HPV vaccination Leadership of the SPMSD GARDASIL / GARDASIL 9 cross functional franchise team, responsible for:- Marketing strategy to drive the growth of GARDASIL- European launch of GARDASIL 9, leading the cross functional team from initial data to in market launch- Policy initiatives to support the role of HPV vaccination

    • United Kingdom
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Commercial Head, Thrombosis, Europe, Asia-Pacific, Japan & Emerging Markets
      • 2011 - 2013

      Commercial head for a portfolio of 2 anticoagulant products globally (ex N America), responsible for turnover in excess of £350m.Led a global team based in France, UK, Poland and TaiwanProducts had multiple indications including Thrombosis and Acute Coronary SyndromeProject leader of divestment of global thrombosis business to Aspen Pharmacare

    • France Business Unit Director, Rare Diseases
      • 2009 - 2011

      Leadership of Sales/Marketing/Medical activities for rare diseases portfolio in France. Key therapy area was Pulmonary Arterial Hypertension and accountability included the launch of Volibris (ambrisentan)Role involved country input to pipeline asset strategy in Duchenne's Muscular Dystrophy (DMD) and Fabry Disease

    • Asthma & Allergy Marketing Director, Asia Pacific & Emerging Markets
      • 2007 - Dec 2008

      Responsible for development and implementation of Seretide asthma brand strategy in China, Asia-Pacific, Australia, Middle East/N Africa, Latin America, Mexico, Turkey & RussiaLaunch of Avamys for allergic rhinitis in Canada, Brazil & Mexico

    • Head of UK Regional Medical Advisors
      • 2006 - 2007

      Management of UK field Medical team, supporting Respiratory and Type 2 Diabetes

    • European Marketing Manager, Type 2 Diabetes
      • 2004 - 2006

      European Marketing Manager, Diabetes (Metabolic Centre of Excellence).Led European Brand Planning and market development strategy, including competitor defence, for AVANDIA, AVANDAMET and other combination products

    • Global Product Strategy Manager
      • 2003 - 2004

      Provided commercial strategy input to R&D teams developing new assets for type 2 diabetes

    • UK Senior Brand Manager, Type 2 Diabetes
      • 2001 - 2003

      Leadership of UK marketing team in Type 2 Diabetes.Areas of focus included brand repositioning, campaign development and salesforce engagement

    • UK Brand Manager, Respiratory Marketing
      • 1999 - 2001

      UK Brand Marketing roles of increasing responsibility to support the launch of SERETIDE in the UK, including brand development, campaign development and salesforce engagement

    • UK Local Disease Management Advisor
      • 1996 - 1999

      Implementation of field based disease management projects in the UK to assess real world outcomes following implementation of disease management protocols.Development, Project management, analysis and presentation of results internally and externally.Projects conducted in asthma, epilepsy, migraine and HIV

    • United States
    • Business Consulting and Services
    • 700 & Above Employee
    • Healthcare sales, sales management and business development roles
      • Oct 1993 - Oct 1996

      Account Manager, Pharmaceuticals and Biotechnology reports, UK and ScandinaviaInterim Sales Manager, German officeHealthcare Consulting Sales Manager Account Manager, Pharmaceuticals and Biotechnology reports, UK and ScandinaviaInterim Sales Manager, German officeHealthcare Consulting Sales Manager

Education

  • University of Bath
    BSc, International Management & Modern Languages (French)
    1989 - 1993
  • Whitgift School
    1981 - 1989

Community

You need to have a working account to view this content. Click here to join now